Global Rheumatoid Arthritis Drugs Market 2016-2020

Description: About Rheumatoid Arthritis Drugs

RA is a chronic inflammatory autoimmune disease seen in people aged between 30 and 60 years. The symptoms of the disease appear slowly, with mild pain around the joints coupled with stiffness and fatigue. In the later stages, it causes inflammation of the joints. Genetic and environmental elements are known to contribute to the development of the condition. DMARDs, NSAIDs, corticosteroids, and analgesics are being developed and administered to treat individuals with RA.

The analysts forecast the global RA drugs market to grow at a CAGR of 3.43% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global RA drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded, generic, and off-label drugs used to treat the disease.

The market is divided into the following segments based on geography:

- Americas
- APAC
- EMEA

The report, Global Rheumatoid Arthritis Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors:

- AbbVie
- Amgen
- Bristol-Myers Squibb (BMS)
- Johnson & Johnson
- Pfizer
- F. Hoffmann-La Roche

Other prominent vendors:

- Ablynx
- Alder BioPharmaceuticals
- Antares Medical Services
- Astellas Pharma
- AstraZeneca
- Boehringer Ingelheim
- Can-Fite BioPharma
- Celgene
- Celltrion
- ChemoCentryx
- Eisai
- Eli Lilly
- Gilead Sciences
- GlaxoSmithKline
- Incyte
- KaloBios Pharmaceuticals
- Lexicon Pharmaceuticals
- Merck
- Morphotek
- Novo Nordisk
- Regeneron Pharmaceuticals
- Sandoz
- Sanofi
- Santarus
- Takeda Pharmaceuticals
- UCB
- Vertex Pharmaceuticals

Market drivers

- Growing older population
- For a full, detailed list, view the full report

Market challenges

- Increasing costs of biologicals
- For a full, detailed list, view the full report

Market trends

- Emergence of biosimilars
- For a full, detailed list, view the full report

Key questions answered in this report

- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
- Novel mechanisms targeted by pipeline candidates
- Clinical trials for RA

PART 08: Market landscape
- Market overview
- Market size and forecast
- Five forces analysis

PART 09: Market segmentation by drug class
- DMARDs
- NSAIDs
- Corticosteroids
- Analgesics
- Others
- Global DMARDs market
- Global NSAIDs market
- Global corticosteroids market
- Global analgesics market

PART 10: Market segmentation by MOA
- TNF inhibitors
- IL-1 blockers
- JAK inhibitors
- Selective costimulation modulators

PART 11: Market segmentation by type of molecule
- Biologics
- Small molecules

PART 12: Market segmentation by ROA
- Oral
- Parenteral
- Topical

PART 13: Market segmentation by dosage form
- Solid
- Liquid
- Semi-solid

PART 14: Geographical segmentation
- RA drugs market in Americas
- RA drugs market in US
- RA drugs market in EMEA
- RA drugs market in Germany
- RA drugs market in UK
- RA drugs market in Spain
- RA drugs market in Italy
- RA drugs market in France
- Rheumatoid arthritis drugs market in APAC
- RA drugs market in Japan
- RA drugs market in Australia
- RA drugs market in India
- RA drugs market in China

PART 15: Key leading countries

PART 16: Market drivers
- Growing older population
- Market dominance of biologics
- Promising drug pipeline
- Changing lifestyle patterns
- Advances in diagnosis technology
PART 17: Impact of drivers

PART 18: Market challenges
- Increasing costs of biologicals
- Loss of patent exclusivity of branded therapies
- Use of complementary and alternative medicines (CAMs)
- Adverse effects of drugs
- Stringent regulations

PART 19: Impact of drivers and challenges

PART 20: Market trends
- Emergence of biosimilars
- Patient assistance programs
- Popularity of off-label and traditional treatment options
- Strategic alliances
- Increase in public awareness

PART 21: Vendor landscape
- Competitive scenario
- Market share analysis 2015
- AbbVie
- Amgen
- BMS
- F. Hoffmann-La Roche
- Johnson & Johnson
- Pfizer
- Other prominent vendors

PART 22: Appendix
- List of abbreviations

PART 23: About Author

List of Exhibits

Exhibit 01: Product offerings
Exhibit 02: Key buying criteria for RA drugs
Exhibit 03: Classification of RA based on disease severity
Exhibit 04: Classification of RA based on disease severity 2016
Exhibit 05: Etiology and pathophysiology of RA
Exhibit 06: Signs and symptoms of RA
Exhibit 07: Diagnostic tests for RA
Exhibit 08: Treatment options for RA
Exhibit 09: Non-pharmacological therapies used for RA
Exhibit 10: Pharmacotherapy therapy for RA
Exhibit 11: Drugs used to treat RA
Exhibit 12: Classification of surgical treatment for RA
Exhibit 13: Percentage share of treatment of RA 2016
Exhibit 14: Historical milestones in treatment of RA
Exhibit 15: Treatment algorithm for RA
Exhibit 16: Economic burden of RA
Exhibit 17: Annual treatment costs of RA within Europe and US 2015 ($)
Exhibit 18: Cost difference between biological DMARDs and non-biological DMARDs
Exhibit 19: Projected prevalence of RA in Americas 2010-2030 ($ millions)
Exhibit 20: New cases of RA in UK per year 2016
Exhibit 21: Existing cases of RA in UK
Exhibit 22: Impact of biologics on various sectors
Exhibit 23: Pipeline molecules for RA
Exhibit 24: Novel targets of pipeline candidates
Exhibit 25: Candidates under development: Baricitinib
Exhibit 26: Candidates under development: Decernotinib
Exhibit 27: Candidates under development: CCX354
Exhibit 91: Usage of CAM in US
Exhibit 92: Side effects associated with RA
Exhibit 93: Impact of drivers and challenges
Exhibit 94: Patient assistance programs offered by companies
Exhibit 95: Revenue share of RA drugs by vendors 2015
Exhibit 96: YoY sales comparison of top drugs 2012-2014 ($ billions)
Exhibit 97: Competitive assessment of top RA drugs
Exhibit 98: Revenue share of RA drugs 2015
Exhibit 99: AbbVie: Product segmentation by revenue 2014
Exhibit 100: AbbVie: YoY revenue and growth rate of Humira 2012-2014 ($ billions)
Exhibit 101: AbbVie: YoY revenue and growth rate of Humira (in US) 2012-2014 ($ billions)
Exhibit 102: AbbVie: YoY revenue and growth rate of Humira (ROW) 2012-2014 ($ billions)
Exhibit 103: Sales of Humira in major markets
Exhibit 104: AbbVie: SWOT analysis
Exhibit 105: Amgen: YoY revenue and growth rate of Enbrel (in US and Canada) 2012-2014 ($ billions)
Exhibit 106: Amgen: YoY revenue and growth rate of Enbrel (in US) 2012-2014 ($ billions)
Exhibit 107: Amgen: YoY revenue and growth rate of Enbrel (in Canada) 2012-2014 ($ millions)
Exhibit 108: Amgen: SWOT analysis
Exhibit 109: BMS: Segmentation by revenue 2014
Exhibit 110: BMS: YoY revenue and growth rate of Orencia 2012-2014 ($ billions)
Exhibit 111: BMS: YoY revenue and growth rate of Orencia (in US) 2012-2014 ($ millions)
Exhibit 112: BMS: YoY revenue and growth rate of Orencia (ROW) 2012-2014 ($ millions)
Exhibit 113: Orencia sales for RA in major markets 2014
Exhibit 114: BMS: SWOT analysis
Exhibit 115: RA products by revenue 2014
Exhibit 116: F. Hoffmann-La Roche: YoY growth and revenue generated from product sales of MabThera/Rituxan 2011-2014 ($ billions)
Exhibit 117: MabThera/Rituxan geographic segmentation by revenue 2014
Exhibit 118: F. Hoffmann-La Roche: YoY revenue and growth rate of Actemra/RoActemra 2012-2014 ($ millions)
Exhibit 119: Actemra/RoActemra geographic segmentation by revenue 2014
Exhibit 120: F. Hoffmann-La Roche: SWOT analysis
Exhibit 121: Johnson & Johnson: Segmentation of key drugs 2014
Exhibit 122: Johnson & Johnson: YoY growth rate and revenue of Remicade 2012-2014 ($ billions)
Exhibit 123: Johnson & Johnson: YoY growth rate and revenue of Remicade (in US) 2012-2014 ($ billions)
Exhibit 124: Johnson & Johnson: YoY growth rate and revenue of Remicade (ROW) 2012-2014 ($ billions)
Exhibit 125: Johnson & Johnson: YoY growth rate and revenue of Simponi/Simponi Aria 2012-2014 ($ millions)
Exhibit 126: Johnson & Johnson: YoY growth rate and revenue of Simponi/Simponi Aria (in US) 2012-2014 ($ millions)
Exhibit 127: Johnson & Johnson: YoY growth rate and revenue of Simponi/Simponi Aria (ROW) 2012-2014 ($ millions)
Exhibit 128: Johnson & Johnson: SWOT analysis
Exhibit 129: Pfizer: Rheumatoid drugs product segmentation by revenue 2014
Exhibit 130: Pfizer: YoY revenue and growth rate of Enbrel (outside US and Canada) 2012-2014 ($ billions)
Exhibit 131: Pfizer: YoY revenue and growth rate of Celebrex 2012-2014 ($ billions)
Exhibit 132: Pfizer: YoY revenue and growth rate of Xeljanz 2012-2014 ($ billions)
Exhibit 133: Pfizer: SWOT analysis

Ordering:

Order Online - http://www.researchandmarkets.com/reports/3623687/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit

http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Global Rheumatoid Arthritis Drugs Market 2016-2020
Web Address: http://www.researchandmarkets.com/reports/3623687/
Office Code: SCPLJFE8

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF)</td>
<td></td>
</tr>
<tr>
<td>Single User</td>
<td>USD 3000</td>
</tr>
<tr>
<td>1 - 5 Users</td>
<td>USD 3500</td>
</tr>
<tr>
<td>Site License</td>
<td>USD 4500</td>
</tr>
<tr>
<td>Enterprisewide</td>
<td>USD 10000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: 
Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof [ ]
First Name: ________________________ Last Name: ________________________
Email Address: * _______________________________
Job Title: _______________________________
Organisation: _______________________________
Address: __________________________________
City: ______________________________________
Postal / Zip Code: ___________________________
Country: ____________________________________
Phone Number: _____________________________
Fax Number: _______________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

- [ ] Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

- [ ] Pay by check: Please post the check, accompanied by this form, to:
  Research and Markets,
  Guinness Center,
  Taylors Lane,
  Dublin 8,
  Ireland.

- [ ] Pay by wire transfer: Please transfer funds to:
  - Account number 833 130 83
  - Sort code 98-53-30
  - Swift code ULSBIE2D
  - IBAN number IE78ULSB98533083313083
  - Bank Address Ulster Bank,
    27-35 Main Street,
    Blackrock,
    Co. Dublin,
    Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World